Vimarsana
Biggest News Aggregation in the World

Page 11 - Medication Errors News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Medication Errors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Medication Errors Today - Breaking & Trending Today

APAC Infusion Pumps Market Report 2022-2027: Featuring Key Players Abbott Laboratories, Cardinal Health, Medtronic & Others - Vimarsana News

APAC Infusion Pumps Market Report 2022-2027: Featuring Key Players Abbott Laboratories, Cardinal Health, Medtronic & Others

/PRNewswire/ -- The "APAC Infusion Pumps Market by Product (Accessories (Dedicated, Non-dedicated), Devices (Volumetric, Insulin, Syringe, Ambulatory)),...

APAC Infusion Pumps Market Report 2022-2027: Featuring Key Players Abbott Laboratories, Cardinal Health, Medtronic & Others - Vimarsana News

APAC Infusion Pumps Market Report 2022-2027: Featuring Key Players Abbott Laboratories, Cardinal Health, Medtronic & Others

/PRNewswire/ -- The "APAC Infusion Pumps Market by Product (Accessories (Dedicated, Non-dedicated), Devices (Volumetric, Insulin, Syringe, Ambulatory)),...

Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID - Vimarsana News

Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID

30.06.2022 - Pfizer Inc. (NYSE: PFE) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of PAXLOVID (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for patients who are at high ...

Brand Institute Executive, a Former FDA Team Leader, Celebrates 15 Years with Company's Subsidiary, Drug Safety Institute - Vimarsana News

Brand Institute Executive, a Former FDA Team Leader, Celebrates 15 Years with Company's Subsidiary, Drug Safety Institute

/PRNewswire/ -- Brand Institute, the global leader in pharmaceutical and healthcare-related name development, recently celebrated the 15-year anniversary of...

Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S. - Vimarsana News

Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Michigan, facility, enabling U.S.-based production in support of its COVID-19 oral treatment, PAXLOVIDTM (nirmatrelvir [PF-07321332] tablets and ...